Related Experiment Video

Updated: Jul 13, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.3K

MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression

Cheng Qiu1, Yong-Dong Feng1, Xi Yang2

  • 1GI Cancer Research Institute, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Current Medical Science
|October 12, 2023
PubMed
Abstract

Insights

MicroRNA-409-5p inhibits gastrointestinal stromal tumor (GIST) growth by targeting KDM4D, reducing angiogenesis. This pathway offers a new strategy for treating imatinib-resistant GIST.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Gastrointestinal stromal tumors (GISTs) exhibit rapid proliferation driven by angiogenesis.
  • MicroRNAs (miRNAs) are implicated in the progression of tumor angiogenesis.
  • Understanding specific miRNA mechanisms in GIST is crucial for therapeutic development.

Purpose of the Study:

  • To elucidate the role of microRNA-409-5p (miR-409-5p) in GIST development and angiogenesis.
  • To identify the molecular targets and signaling pathways influenced by miR-409-5p in GIST cells.

Main Methods:

  • Comparative analysis of miR-409-5p expression in GIST tissues versus adjacent tissues.
  • Prediction and validation of miR-409-5p target genes.
  • Functional studies in GIST cell lines (GIST-T1, GIST882) using lentiviral transfection.
  • Assessment of angiogenesis-related protein expression via Western blotting and ELISA.

Main Results:

  • miR-409-5p expression was significantly decreased in GIST tissues.
  • Upregulation of miR-409-5p inhibited hypoxia-inducible transcription factor 1β (HIF1β) and vascular endothelial growth factor A (VEGF-A) protein levels.
  • miR-409-5p directly targets Lysine-specific demethylase 4D (KDM4D) mRNA, inhibiting angiogenesis.
  • Combination therapy of miR-409-5p and imatinib enhanced anti-angiogenic effects.

Conclusions:

  • The miR-409-5p/KDM4D/HIF1β/VEGF-A pathway is a novel mechanism in GIST angiogenesis.
  • This pathway represents a potential therapeutic target for overcoming imatinib resistance in GIST.
Keywords:
KDM4Dgastrointestinal stromal tumormicroRNA-409-5p

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.1K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K